Literature DB >> 6995491

An experimental model for ascending acute pyelonephritis caused by Escherichia coli or proteus in rats.

P Larsson, B Kaijser, I M Baltzer, S Olling.   

Abstract

Experimental, ascending acute pyelonephritis in rats was produced by injecting 0 x 5 ml of 10(9) bacteria/ml into the urinary bladder via the urethra. No traumatic manipulation of the ureters of kidneys was necessary. A grading system for kidney lesions based on macro- and microscopical examination was used. The capacity of different Escherichia coli and proteus strains to induce acute pyelonephritis was tested, and the E. coli 06K13H1 strain and the Proteus mirabilis 03H1 strain were especially capable of causing urinary tract infection. For the P. mirabilis 03H1 strain, a dominance of right kidney lesions was noted in contrast to the E. coli 06K13H1 strain which did not show any side preference.

Entities:  

Mesh:

Year:  1980        PMID: 6995491      PMCID: PMC1146089          DOI: 10.1136/jcp.33.4.408

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  Experimental pyelonephritis in the rat with observations on ureteral reflux.

Authors:  J L SOMMER
Journal:  J Urol       Date:  1961-10       Impact factor: 7.450

2.  Experimental pyelonephritis: a new method for inducing pyelonephritis in the rat.

Authors:  T E Miller; K B Robinson
Journal:  J Infect Dis       Date:  1973-03       Impact factor: 5.226

3.  Experimental hematogenous pyelonephritis due to Escherichia coli in rabbits: the antibody response and its protective capacity.

Authors:  B Kaijser; S Olling
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

4.  [Serum resistance and "nephropathogenicity" of antigenetically defined E. coli strains. 3. Experimental pyelonephritis with differently serum resistant bacilli].

Authors:  W Henkel; R Commichau
Journal:  Z Med Mikrobiol Immunol       Date:  1971

5.  [Comparative studies on hematogenous and ascending pyelonephritis in rats].

Authors:  C P Adler; H Ritzmann; H U Zollinger
Journal:  Virchows Arch A Pathol Pathol Anat       Date:  1969

6.  Antibiotic therapy of Escherichia coli pyelonephritis produced in mice undergoing chronic diuresis.

Authors:  E G Hubert; G M Kalmanson; L B Guze
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

7.  The significance of urease in proteus pyelonephritis: a bacteriological study.

Authors:  D M MacLaren
Journal:  J Pathol Bacteriol       Date:  1968-07

8.  The role of vesico-ureteric (V-U) reflux in the pathogenesis of kidney scars in the rat.

Authors:  M Morgan; A W Asscher; D B Moffat
Journal:  Nephron       Date:  1976       Impact factor: 2.847

9.  Characteristics of antibiotic-resistant Escherichia coli in the rectum of healthy school-children.

Authors:  G Lidin-Janson; E Falsen; U Jodal; B Kaijser; K Lincoln
Journal:  J Med Microbiol       Date:  1977-08       Impact factor: 2.472

10.  THE ROLE OF IMMUNITY IN THE PATHOGENESIS OF EXPERIMENTAL RETROGRADE PYELONEPHRITIS.

Authors:  B W HUNTER; L L AKINS; J P SANFORD
Journal:  J Exp Med       Date:  1964-01-01       Impact factor: 14.307

View more
  11 in total

1.  Experimental Escherichia coli ascending pyelonephritis in rats: changes in bacterial properties and the immune response to surface antigens.

Authors:  I Mattsby-Baltzer; L A Hanson; B Kaijser; P Larsson; S Olling; C Svanborg-Edén
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

2.  Experimental Escherichia coli ascending pyelonephritis in rats: active peroral immunization with live Escherichia coli.

Authors:  I Mattsby-Baltzer; L A Hanson; S Olling; B Kaijser
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

3.  Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis.

Authors:  Karishma Gupta; Shannon B Donnola; Zhina Sadeghi; Lan Lu; Bernadette O Erokwu; Michael Kavran; Adonis Hijaz; Chris A Flask
Journal:  J Vis Exp       Date:  2017-07-18       Impact factor: 1.355

4.  99mTechnetium dimercaptosuccinic acid scintigraphy in the diagnosis of acute pyelonephritis in rats.

Authors:  I Wikstad; L Hannerz; A Karlsson; A C Eklöf; S Olling; A Aperia
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

5.  Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.

Authors:  D Gargallo; M Moros; R Coll; M Esteve; J Parés; M A Xicota; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Protection against acute, ascending pyelonephritis caused by Escherichia coli in rats, using isolated capsular antigen conjugated to bovine serum albumin.

Authors:  B Kaijser; P Larsson; S Olling; R Schneerson
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

7.  Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin.

Authors:  L Hagberg; I Engberg; R Freter; J Lam; S Olling; C Svanborg Edén
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Comparative Pharmacokinetics of Gallic Acid, Protocatechuic Acid, and Quercitrin in Normal and Pyelonephritis Rats after Oral Administration of a Polygonum capitatum Extract.

Authors:  Yong Huang; Zuying Zhou; Wu Yang; Zipeng Gong; Yueting Li; Siying Chen; Yonglin Wang; Aimin Wang; Yanyu Lan; Ting Liu; Lin Zheng
Journal:  Molecules       Date:  2019-10-27       Impact factor: 4.411

9.  Efficacy of Human Exposures of Gepotidacin (GSK2140944) against Escherichia coli in a Rat Pyelonephritis Model.

Authors:  Jennifer L Hoover; Christine M Singley; Philippa Elefante; Stephen Rittenhouse
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

10.  Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses.

Authors:  Radwa N Morgan; Sarra E Saleh; Hala A Farrag; Mohammad M Aboulwafa
Journal:  Gut Pathog       Date:  2019-05-19       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.